Bisoprolol and Metoprolol Show Equivalent Blood Pressure Reduction in Hypertension
Both bisoprolol and metoprolol are effective beta-blockers for blood pressure reduction in hypertension, with no clinically significant difference in overall BP-lowering efficacy between the two agents. However, they differ in their pharmacokinetic profiles, which may influence dosing convenience and duration of action.
Blood Pressure Reduction: Equivalent Efficacy
The evidence demonstrates comparable antihypertensive effects between these agents:
Overall BP reduction: A head-to-head trial showed bisoprolol achieved mean reductions of 31.8/21.2 mmHg (systolic/diastolic) versus metoprolol's 28.0/20.6 mmHg when combined with hydrochlorothiazide—differences that were not clinically significant 1.
24-hour efficacy: Simulation modeling of ambulatory blood pressure monitoring found no significant difference in mean 24-hour systolic BP between the two drugs (estimated difference 2.7 mmHg, 95% CI -0.3 to 5.7 mmHg; p=0.08) 2.
Diurnal patterns differ: Bisoprolol demonstrates more sustained BP control in the last 4 hours of the dosing interval (residual effects 86-93% of peak) compared to metoprolol (53-66% of peak), reflecting bisoprolol's longer half-life 3. This translates to more consistent 24-hour coverage with bisoprolol, while metoprolol shows greater efficacy earlier in the dosing interval 2.
Recommended Dosing
According to the 2017 ACC/AHA Hypertension Guidelines 4, 5, 6, 7, 8:
Bisoprolol:
- Starting dose: 2.5 mg once daily
- Target dose: 2.5-10 mg once daily
- Frequency: Once daily dosing
Metoprolol succinate (extended-release):
- Starting dose: 50 mg once daily
- Target dose: 50-200 mg once daily
- Frequency: Once daily dosing
Metoprolol tartrate (immediate-release):
- Starting dose: 100 mg
- Target dose: 100-200 mg
- Frequency: Twice daily dosing
Clinical Context: Beta-Blockers Are NOT First-Line for Uncomplicated Hypertension
A critical caveat: Beta-blockers are explicitly not recommended as first-line agents for hypertension unless the patient has compelling indications such as ischemic heart disease or heart failure 4, 5, 6, 7, 8. The 2017 ACC/AHA guidelines clearly state that thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers are the preferred initial agents for uncomplicated hypertension.
When Beta-Blockers ARE Indicated:
Compelling indications where bisoprolol or metoprolol succinate are preferred 9, 10:
- Heart failure with reduced ejection fraction (HFrEF): Both bisoprolol and metoprolol succinate (along with carvedilol) have proven mortality benefit 11, 9, 12, 10
- Post-myocardial infarction: Guideline-directed medical therapy
- Stable ischemic heart disease with angina: For symptom control and BP management 13
For heart failure specifically, the Canadian guidelines recommend bisoprolol starting at 1.25 mg daily, titrating to 10 mg daily, while metoprolol CR/XL starts at 12.5-25 mg daily, titrating to 200 mg daily 11.
Practical Considerations
Bisoprolol advantages:
- True once-daily dosing with more consistent 24-hour coverage 3
- Longer duration of action (half-life 10-12 hours) 14
- More sustained heart rate and BP control in the last hours before next dose 15, 3
Metoprolol considerations:
- Metoprolol succinate (extended-release) is required for once-daily dosing and proven mortality benefit in heart failure
- Metoprolol tartrate (immediate-release) requires twice-daily dosing and lacks the same evidence base for heart failure
- More variable pharmacokinetics, particularly in patients with hepatic impairment 14
Safety Profile
Both agents demonstrate similar adverse event profiles 15, 1:
- Bradycardia, fatigue, dizziness are dose-related
- No clinically significant metabolic changes
- Contraindicated in asthma, second/third-degree heart block, severe bradycardia
- COPD is not an absolute contraindication for cardioselective beta-blockers 12
Bottom line: Choose bisoprolol 2.5-10 mg once daily or metoprolol succinate 50-200 mg once daily based on patient-specific factors, but only use beta-blockers for hypertension when compelling cardiac indications exist. For pure BP reduction without comorbidities, use first-line agents (thiazides, ACE inhibitors, ARBs, or calcium channel blockers) instead.